Characterization and comparison of commercially available TNF receptor 2-Fc fusion protein products
Published 2012 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Characterization and comparison of commercially available TNF receptor 2-Fc fusion protein products
Authors
Keywords
-
Journal
mAbs
Volume 4, Issue 6, Pages 761-774
Publisher
Informa UK Limited
Online
2012-11-02
DOI
10.4161/mabs.22276
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Rapid comparison of a candidate biosimilar to an innovator monoclonal antibody with advanced liquid chromatography and mass spectrometry technologies
- (2014) Hongwei Xie et al. mAbs
- Biosimilar, Biobetter, and Next Generation Antibody Characterization by Mass Spectrometry
- (2012) Alain Beck et al. ANALYTICAL CHEMISTRY
- Biosimilars: Impact of Biologic Product Life Cycle and European Experience on the Regulatory Trajectory in the United States
- (2012) Islah Ahmed et al. CLINICAL THERAPEUTICS
- Analytical tools for characterizing biopharmaceuticals and the implications for biosimilars
- (2012) Steven A. Berkowitz et al. NATURE REVIEWS DRUG DISCOVERY
- Bioequivalence of two recombinant granulocyte colony-stimulating factor products after subcutaneous injection in healthy volunteers
- (2011) H. Lubenau et al. INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS
- Acceptable changes in quality attributes of glycosylated biopharmaceuticals
- (2011) Martin Schiestl et al. NATURE BIOTECHNOLOGY
- Comparison of the pharmacodynamic profiles of a biosimilar filgrastim and Amgen filgrastim: results from a randomized, phase I trial
- (2010) Cornelius F. Waller et al. ANNALS OF HEMATOLOGY
- Pharmacokinetic profiles of a biosimilar filgrastim and Amgen filgrastim: results from a randomized, phase I trial
- (2010) Cornelius F. Waller et al. ANNALS OF HEMATOLOGY
- Physicochemical and Biologic Comparability of a Biosimilar Granulocyte Colony-Stimulating Factor with Its Reference Product
- (2010) Fritz Sörgel et al. BIODRUGS
- Comparison of the physicochemical properties of a biosimilar filgrastim with those of reference filgrastim
- (2010) A. Skrlin et al. BIOLOGICALS
- Bioequivalence Studies of Omnitrope, the First Biosimilar/rhGH Follow-on Protein: Two Comparative Phase 1 Randomized Studies and Population Pharmacokinetic Analysis
- (2010) Richard Stanhope et al. JOURNAL OF CLINICAL PHARMACOLOGY
- European Medicines Agency workshop on biosimilar monoclonal antibodies
- (2010) Janice M. Reichert et al. mAbs
- Antibodies to watch in 2010
- (2010) Janice M. Reichert mAbs
- A Phase III Randomized Equivalence Study of Biosimilar Filgrastim versus Amgen Filgrastim in Patients Receiving Myelosuppressive Chemotherapy for Breast Cancer
- (2010) Cornelius F. Waller et al. Oncology Research and Treatment
- Development of a new G-CSF product based on biosimilarity assessment
- (2009) P. Gascon et al. ANNALS OF ONCOLOGY
- Pharmacokinetic and Pharmacodynamic Profile of New Biosimilar Filgrastim XM02 Equivalent to Marketed Filgrastim Neupogen®
- (2009) Heinz Lubenau et al. BIODRUGS
- Seven Years of Safety and Efficacy of the Recombinant Human Growth Hormone Omnitrope® in the Treatment of Growth Hormone Deficient Children: Results of a Phase III Study
- (2009) T. Romer et al. Hormone Research in Paediatrics
- Biosimilars: Policy, clinical, and regulatory considerations
- (2008) S. Gottlieb AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY
- Comparison of the therapeutic effects of epoetin zeta to epoetin alfa in the maintenance phase of renal anaemia treatment
- (2008) Volker Wizemann et al. CURRENT MEDICAL RESEARCH AND OPINION
- Comparison of the therapeutic effects of epoetin zeta and epoetin alfa in the correction of renal anaemia
- (2008) Stefan Krivoshiev et al. CURRENT MEDICAL RESEARCH AND OPINION
- Terminal sugars of Fc glycans influence antibody effector functions of IgGs
- (2008) T Shantha Raju CURRENT OPINION IN IMMUNOLOGY
- Trends in Glycosylation, Glycoanalysis and Glycoengineering of Therapeutic Antibodies and Fc-Fusion Proteins
- (2008) Alain Beck et al. CURRENT PHARMACEUTICAL BIOTECHNOLOGY
- Effects of three anti-TNF-α drugs: Etanercept, infliximab and pirfenidone on release of TNF-α in medium and TNF-α associated with the cell in vitro
- (2008) K.J. Grattendick et al. INTERNATIONAL IMMUNOPHARMACOLOGY
- Monoclonal Antibodies in Cancer Therapy: 25 Years of Progress
- (2008) Robert K. Oldham et al. JOURNAL OF CLINICAL ONCOLOGY
- Tumor necrosis factor antagonist mechanisms of action: A comprehensive review
- (2007) Daniel Tracey et al. PHARMACOLOGY & THERAPEUTICS
- Glycosylation of Recombinant Antibody Therapeutics
- (2005) Royston Jefferis BIOTECHNOLOGY PROGRESS
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now